Horizon Pharma Buys Raptor
For the week ending September 16, 2016, a combined $1.01 billion was spent on three pharmaceutical deals, one of which is also the largest pharmaceutical deal so far in September. Horizon Pharma plc (NASDAQ: HZNP), which develops, acquires and commercializes medicines for the treatment of arthritis, pain, inflammatory and/or orphan diseases, acquired Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) for approximately $800 million, or $9.00 per share. Raptor focuses on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The transaction gives Horizon global rights to PROCYSBI® delayed-release capsules, used to treat nephropathic... Read More »Stryker’s Minimally Invasive Acquisitions
For a company that has targeted minimally invasive surgical products of late, Stryker Corporation (NYSE: SYK) has been highly visible in the acquisition arena this year. It started in February 2016. That month, the medical device giant announced three deals, totaling $2.03 billion. In April, three more acquisitions were announced, with only one disclosed price of $40.6 million. Halfway through September, the company has made two more acquisitions, for undisclosed prices. For those keeping score, that’s eight deals for approximately $4.1 billion. Stryker’s most recent deals have targeted Ivy Sports Medicine, LLC for its minimally invasive meniscal repair platform, and Restore... Read More »Allergan Eyes Clinical-Stage Ocular Drugs
Allergan plc (NYSE: AGN) just purchased privately-held RetroSense Therapeutics LLC for $60 million in an all-cash transaction, with potential regulatory and commercialization milestone payments. Based in Ann Arbor Michigan, RetroSense is a clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in those suffering from blindness. Its lead development program, RST-001, is a novel gene therapy for the potential treatment of Retinitis Pigmentosa (RP). The acquisition gives Allergan global rights to RetroSense’s lead product candidate, RST-001. In 2014, RST-001 received Orphan Drug Designation by the U.S. FDA for the treatment of Retinitis... Read More »Fresensius Helios Adds 43 Spanish Hospitals
Fresenius Helios (EXTRA: FRE.DE) was already the largest private hospital company in Europe, and now it’s grown even larger. On September 5, 2016, the company announced the acquisition of Quirónsalud, Spain’s largest private hospital operator, with 43 hospitals, 39 outpatient centers, and 300 occupational risk prevention centers. Quirónsalud was created by the 2014 merger of IDC Salud and Grupo Hospitalario Quirón. Fresenius Helios, a division of Fresenius SE & Co. KGaA, vaulted to the top of the private European hospital market in September 2013, following the its acquisition of 43 hospitals and 15 outpatient facilities in Germany, sold by Rhön Klinikum AG, for... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
